Differentiating Reactive Arthritis from Rheumatoid Arthritis

Key Clinical Distinctions

The American College of Rheumatology recommends that Rheumatoid Arthritis be diagnosed using the 2010 ACR/EULAR Classification Criteria, which requires ≥6/10 points, including joint involvement, serology, acute phase reactants, and duration ≥6 weeks 2
The European League Against Rheumatism suggests that Rheumatoid Arthritis diagnosis should not be delayed waiting for positive serology, as seronegative RA is common (20-30%) and has a similar prognosis 2
The American College of Rheumatology states that Rheumatoid Arthritis typically involves symmetric polyarthritis of small joints, including metacarpophalangeal, proximal interphalangeal, wrists, and metatarsophalangeal joints, with morning stiffness lasting ≥1 hour 1
The American College of Rheumatology notes that Rheumatoid Arthritis can also affect large joints, but in a symmetric distribution, and that carpal and pericapitate abnormalities can develop progressively, with ankylosis occurring after 1.5-3 years 3

The American College of Rheumatology recommends applying the 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis diagnosis, which includes joint involvement (0-5 points), serology (0-3 points), acute phase reactants (0-1 point), and duration ≥6 weeks (1 point) 2
The European League Against Rheumatism suggests performing a squeeze test of metacarpophalangeal and metatarsophalangeal joints to assess for clinical synovitis 2
The American College of Rheumatology recommends obtaining baseline imaging, including bilateral hand, wrist, and foot X-rays, to detect erosions and monitor progression 2

The American College of Rheumatology recommends immediate initiation of methotrexate 15-30 mg/week as the anchor drug and first-line therapy for Rheumatoid Arthritis, with short-term low-dose glucocorticoids as bridge therapy 2
The European League Against Rheumatism suggests that the treatment target for Rheumatoid Arthritis should be sustained remission (SDAI ≤3.3, CDAI ≤2.8, or DAS28 <2.6) or low disease activity (SDAI ≤11) 2
The American College of Rheumatology recommends monitoring disease activity every 1-3 months using composite measures (DAS28, SDAI, CDAI) and adjusting therapy if no improvement is seen by 3 months or the target is not reached by 6 months 4

The American College of Rheumatology warns against delaying treatment for Rheumatoid Arthritis while waiting for positive serology, as seronegative RA is common and has a similar prognosis 2
The European League Against Rheumatism cautions against dismissing a diagnosis of Rheumatoid Arthritis based on normal ESR/CRP, as acute phase reactants can be normal even in active disease 2
The American College of Rheumatology advises considering alternative diagnoses in seronegative disease, including psoriatic arthritis, spondyloarthritis, crystal arthropathies, polymyalgia rheumatica, and Still's disease 5